Latest & greatest articles for proton pump inhibitors

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on proton pump inhibitors or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on proton pump inhibitors and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for proton pump inhibitors

41. The efficacy of vonoprazan, a potent acid blocker, compared to proton pump inhibitors, for Helicobacter pylori eradication therapy involving clarithromycin-resistant strains: a systematic review and meta-analysis

The efficacy of vonoprazan, a potent acid blocker, compared to proton pump inhibitors, for Helicobacter pylori eradication therapy involving clarithromycin-resistant strains: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated

2018 PROSPERO

42. Long-term proton pump inhibitors use and risk of gastric cancer and progression of chronic kidney disease: systematic review and meta-analysis

Long-term proton pump inhibitors use and risk of gastric cancer and progression of chronic kidney disease: systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2018 PROSPERO

43. Pneumonia caused by proton pump inhibitors (PPI)

Pneumonia caused by proton pump inhibitors (PPI) MED CHECK - TIP December 2017 / Vol.3 No.9 · Page 27 -The Informed Prescriber C N o 9 M ED HECK D e ce m b e r 2 0 1 7 WHO downgrades Tamiflu Suvorexant : A hypnotic causing cataplexy Insomnia, Sleep Duration, Harm of hypnotics PPI causes Pneumonia Editorial WHO downgraded oseltamivir (Tamiflu) New Products Hypnotic (sleeping pill), suvorexant (brand name Belsomra) A substance that causes narcolepsy and cataplexy Teriparatide More harm than (...) benefit: Review Insomnia, Optimal Sleep Duration and Harm of Sleeping pills Pneumonia caused by proton pump inhibitors (PPI) (1) meta-analysis (2) Critical appraisal of a study CONTENTS (December 2017, Vol. 3, No. 9 ) 28 29 34 36 40 42 Volume 3 Page 28 · MED CHECK - TIP December 2017/ Vol.3 No.9 WHO downgrades Tamiflu after reviewing evidence WHO (World Health Organization) reviews their model list of essential medicines every two years. In the revision launched in June 2017, oseltamivir (Tamiflu

2018 Med Check - The Informed Prescriber

44. A systematic review of antenatal proton pump inhibitors (PPIs) for the prevention and treatment of preeclampsia and gestational hypertension

A systematic review of antenatal proton pump inhibitors (PPIs) for the prevention and treatment of preeclampsia and gestational hypertension Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2018 PROSPERO

45. Systematic review of efficacy and safety of vonoprazan compared to proton pump inhibitors

Systematic review of efficacy and safety of vonoprazan compared to proton pump inhibitors Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing

2018 PROSPERO

46. Association between chronic use of proton pump inhibitors and the risk of gastric cancer

Association between chronic use of proton pump inhibitors and the risk of gastric cancer Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing

2018 PROSPERO

47. The use of proton-pump inhibitors (PPI) in pregnancy and the risk of neonatal adverse events: a systematic review and meta-analysis

The use of proton-pump inhibitors (PPI) in pregnancy and the risk of neonatal adverse events: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2018 PROSPERO

48. Proton pump inhibitors use and adverse outcomes: an umbrella review of systematic reviews and meta-analyses

Proton pump inhibitors use and adverse outcomes: an umbrella review of systematic reviews and meta-analyses Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation

2018 PROSPERO

49. The association between proton pump inhibitor (PPI) use and risk of liver cancer: a protocol for a systematic review and meta-analysis

The association between proton pump inhibitor (PPI) use and risk of liver cancer: a protocol for a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2018 PROSPERO

50. Vonoprazan versus proton pump inhibitors in treating post-endoscopic submucosal dissection (ESD) ulcers and bleeding: protocol for a meta-analysis of randomized controlled trials and observational studies

Vonoprazan versus proton pump inhibitors in treating post-endoscopic submucosal dissection (ESD) ulcers and bleeding: protocol for a meta-analysis of randomized controlled trials and observational studies Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files

2018 PROSPERO

51. Meta-analysis of the efficacy of prokinetic drugs combined with proton pump inhibitors and proton pump inhibitors alone in the treatment of gastroesophageal reflux disease

Meta-analysis of the efficacy of prokinetic drugs combined with proton pump inhibitors and proton pump inhibitors alone in the treatment of gastroesophageal reflux disease Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation

2018 PROSPERO

52. Proton pump inhibitors and the risk of dementia: update of a meta-analysis

Proton pump inhibitors and the risk of dementia: update of a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect

2018 PROSPERO

53. The association between proton pump inhibitor use and mortality in patient with cirrhosis: a protocol for a systematic review and meta-analysis

The association between proton pump inhibitor use and mortality in patient with cirrhosis: a protocol for a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2018 PROSPERO

54. Effects of proton pump inhibitor on outcomes of kidney transplant recipients

Effects of proton pump inhibitor on outcomes of kidney transplant recipients Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect

2018 PROSPERO

55. Non-Pharmacological Alternatives to Proton Pump Inhibitors: Comparative Clinical Effectiveness and Guidelines

Non-Pharmacological Alternatives to Proton Pump Inhibitors: Comparative Clinical Effectiveness and Guidelines Non-Pharmacological Alternatives to Proton Pump Inhibitors: Comparative Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Non-Pharmacological Alternatives to Proton Pump Inhibitors: Comparative Clinical Effectiveness and Guidelines Non-Pharmacological Alternatives to Proton Pump Inhibitors: Comparative Clinical Effectiveness and Guidelines Last updated: May (...) 11, 2018 Project Number: RB1217-000 Product Line: Research Type: Devices and Systems Report Type: Summary of Abstracts Result type: Report Question What is the comparative clinical effectiveness of non-pharmacological or alternative interventions compared to proton pump inhibitors for patients with disorders of excessive acid secretion? What are the evidence-based guidelines for non-pharmacological or alternative interventions for patient with excessive acid secretion? Key Message One non

2018 Canadian Agency for Drugs and Technologies in Health - Rapid Review

56. General medicine: Proton pump inhibitor therapy after Helicobacter pylori eradication may increase the risk of gastric cancer

General medicine: Proton pump inhibitor therapy after Helicobacter pylori eradication may increase the risk of gastric cancer Proton pump inhibitor therapy after Helicobacter pylori eradication may increase the risk of gastric cancer | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Proton pump inhibitor therapy after Helicobacter pylori eradication may increase the risk of gastric cancer Article Text Commentary General medicine

2018 Evidence-Based Medicine

57. A Clinical Trial of Proton Pump Inhibitors to Treat Children with Chronic Otitis Media with Effusion. Full Text available with Trip Pro

A Clinical Trial of Proton Pump Inhibitors to Treat Children with Chronic Otitis Media with Effusion. Gastroesophageal reflux (GER) is considered a cause of otitis media with effusion (OME). This study aimed to investigate whether OME can be effectively treated with a proton pump inhibitor (PPI), therefore implicating GER as a causative factor of OME.A PPI or placebo was randomly administered to enrolled subjects for 4-8 weeks. To monitor effusion status, subjects underwent monthly pneumatic

2018 The journal of international advanced otology Controlled trial quality: uncertain

58. Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study Full Text available with Trip Pro

Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study Proton pump inhibitors (PPIs) is associated with worsening of gastric atrophy, particularly in Helicobacter pylori (HP)-infected subjects. We determined the association between PPIs use and gastric cancer (GC) among HP-infected subjects who had received HP therapy.This study was based on a territory-wide health database of Hong Kong. We identified adults who

2017 EvidenceUpdates

59. Proton pump inhibitors for functional dyspepsia. Full Text available with Trip Pro

Proton pump inhibitors for functional dyspepsia. Functional dyspepsia (FD or non-ulcer dyspepsia) is defined as continuous or frequently recurring epigastric pain or discomfort for which no organic cause can be found. Acid suppressive therapy, including proton pump inhibitors (PPIs), has been proposed as a therapeutic option in FD, but its efficacy remains controversial. While PPIs are generally considered safe and well tolerated, they have been associated with adverse events, especially (...) in the long term. For this reason, decisions on whether to initiate or continue PPI therapy should be made based on an appropriate clinical indication. Therefore, we conducted a systematic review to evaluate whether PPI therapy provides symptomatic relief in FD.To determine the efficacy of proton pump inhibitors in the improvement of global symptoms of dyspepsia and quality of life compared to placebo, H2 receptor antagonists or prokinetics, in people with functional dyspepsia.We searched in the following

2017 Cochrane

60. Proton Pump Inhibitor Usage and the Risk of Mortality in Hemodialysis Patients Full Text available with Trip Pro

Proton Pump Inhibitor Usage and the Risk of Mortality in Hemodialysis Patients Long-term inappropriate proton pump inhibitors use (PPIs) is a matter of concern because of the risks associated with their long-term use in older patients with chronic conditions. The risk of PPI treatment in hemodialysis patients remains unexplored.We assessed the relationship between the use of PPIs and the risk of death in hemodialysis patients throughout a retrospective multicenter propensity score-matched study

2017 Kidney international reports